Latest Insider Transactions at Kura Oncology, Inc. (KURA)
This section provides a real-time view of insider transactions for Kura Oncology, Inc. (KURA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kura Oncology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kura Oncology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2024
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,615
-3.65%
|
$57,530
$22.15 P/Share
|
|
Jan 30
2024
|
Stephen Dale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,825
-11.06%
|
$101,325
$21.55 P/Share
|
|
Jan 29
2024
|
Stephen Dale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,158
-7.3%
|
$121,686
$17.8 P/Share
|
|
Jan 29
2024
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,496
-6.48%
|
$25,432
$17.8 P/Share
|
|
Jan 29
2024
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,053
-2.89%
|
$34,901
$17.8 P/Share
|
|
Jan 29
2024
|
Thomas James Doyle SVP, Finance & Accounting |
SELL
Open market or private sale
|
Direct |
2,318
-1.56%
|
$39,406
$17.8 P/Share
|
|
Jan 24
2024
|
Troy Edward Wilson President and CEO |
SELL
Open market or private sale
|
Direct |
91,052
-95.95%
|
$1,821,040
$20.23 P/Share
|
|
Jan 24
2024
|
Troy Edward Wilson President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
91,052
+48.95%
|
$455,260
$5.48 P/Share
|
|
Jan 02
2024
|
Teresa Brophy Bair Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+39.43%
|
-
|
|
Jan 02
2024
|
Brian T. Powl Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Jan 02
2024
|
Thomas James Doyle SVP, Finance & Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
21,250
+29.65%
|
-
|
|
Dec 07
2023
|
Troy Edward Wilson President and CEO |
SELL
Bona fide gift
|
Indirect |
1,000
-0.36%
|
-
|
|
Dec 07
2023
|
Troy Edward Wilson President and CEO |
SELL
Bona fide gift
|
Direct |
2,000
-78.16%
|
-
|
|
Jun 16
2023
|
Thomas Malley |
BUY
Open market or private purchase
|
Indirect |
50,000
+26.38%
|
$550,000
$11.5 P/Share
|
|
Jun 02
2023
|
Troy Edward Wilson President and CEO |
SELL
Other acquisition or disposition
|
Direct |
27,966
-91.62%
|
-
|
|
Jun 02
2023
|
Troy Edward Wilson President and CEO |
BUY
Other acquisition or disposition
|
Indirect |
308,394
+25.37%
|
-
|
|
Jun 02
2023
|
Troy Edward Wilson President and CEO |
SELL
Other acquisition or disposition
|
Indirect |
862,212
-41.78%
|
-
|
|
Feb 16
2023
|
Teresa Brophy Bair Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,125
+50.0%
|
-
|
|
Feb 16
2023
|
Thomas James Doyle SVP, Finance & Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
10,625
+27.89%
|
-
|
|
Feb 16
2023
|
Stephen Dale Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,125
+31.28%
|
-
|
|
Jan 27
2023
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,821
-7.91%
|
$23,673
$13.89 P/Share
|
|
Jan 27
2023
|
Kirsten Flowers CCO & Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
1,906
-8.47%
|
$24,778
$13.89 P/Share
|
|
Jan 27
2023
|
Stephen Dale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,225
-13.38%
|
$119,925
$13.88 P/Share
|
|
Jan 27
2023
|
Thomas James Doyle SVP, Finance & Accounting |
SELL
Open market or private sale
|
Direct |
1,548
-4.3%
|
$20,124
$13.89 P/Share
|
|
Nov 17
2022
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,100
-100.0%
|
$31,500
$15.22 P/Share
|
|
Oct 06
2022
|
Troy Edward Wilson President and CEO |
BUY
Other acquisition or disposition
|
Indirect |
1,084,300
+49.07%
|
-
|
|
Oct 06
2022
|
Troy Edward Wilson President and CEO |
SELL
Other acquisition or disposition
|
Indirect |
1,084,300
-99.23%
|
-
|
|
Aug 19
2022
|
Troy Edward Wilson President and CEO |
SELL
Other acquisition or disposition
|
Direct |
11,985
-28.19%
|
-
|
|
Aug 19
2022
|
Troy Edward Wilson President and CEO |
BUY
Other acquisition or disposition
|
Indirect |
41,318
+50.0%
|
-
|
|
Aug 19
2022
|
Troy Edward Wilson President and CEO |
SELL
Other acquisition or disposition
|
Indirect |
59,026
-2.59%
|
-
|
|
Jul 14
2022
|
Troy Edward Wilson President and CEO |
SELL
Other acquisition or disposition
|
Indirect |
468,297
-28.91%
|
-
|
|
Feb 07
2022
|
Thomas James Doyle SVP, Finance & Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
8,390
+35.87%
|
-
|
|
Jan 26
2022
|
Stephen Dale Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,900
+50.0%
|
-
|
|
Jan 26
2022
|
Kirsten Flowers CCO & Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,900
+49.31%
|
-
|
|
Jan 26
2022
|
Kathleen Ford Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,900
+48.74%
|
-
|
|
Jan 26
2022
|
Marc Grasso CFO, CBO |
BUY
Grant, award, or other acquisition
|
Direct |
21,900
+50.0%
|
-
|
|
Mar 15
2021
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,250
-100.0%
|
$181,250
$29.43 P/Share
|
|
Mar 15
2021
|
Kathleen Ford Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+50.0%
|
$118,750
$19.43 P/Share
|
|
Dec 23
2020
|
Troy Edward Wilson President and CEO |
SELL
Other acquisition or disposition
|
Indirect |
175,000
-9.75%
|
-
|
|
Dec 15
2020
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
9,375
-100.0%
|
$375,000
$40.6 P/Share
|
|
Dec 15
2020
|
Kathleen Ford Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+50.0%
|
$178,125
$19.43 P/Share
|
|
Dec 01
2020
|
Troy Edward Wilson President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,855
+22.88%
|
$71,130
$6.15 P/Share
|
|
Nov 10
2020
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,250
-100.0%
|
$243,750
$39.43 P/Share
|
|
Nov 10
2020
|
Kathleen Ford Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+50.0%
|
$118,750
$19.43 P/Share
|
|
Oct 08
2020
|
Troy Edward Wilson President and CEO |
SELL
Open market or private sale
|
Direct |
50,370
-64.19%
|
$1,712,580
$34.0 P/Share
|
|
Oct 08
2020
|
Troy Edward Wilson President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,370
+39.1%
|
$302,220
$6.15 P/Share
|
|
Oct 08
2020
|
Troy Edward Wilson President and CEO |
SELL
Open market or private sale
|
Indirect |
106,736
-100.0%
|
$3,629,024
$34.0 P/Share
|
|
Oct 07
2020
|
Troy Edward Wilson President and CEO |
SELL
Open market or private sale
|
Direct |
4,586
-14.03%
|
$155,924
$34.0 P/Share
|
|
Oct 07
2020
|
Troy Edward Wilson President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,586
+12.31%
|
$27,516
$6.15 P/Share
|
|
Oct 07
2020
|
Troy Edward Wilson President and CEO |
SELL
Open market or private sale
|
Indirect |
99,900
-48.35%
|
$3,196,800
$32.0 P/Share
|